Novel alternative scaffolds and their potential use for tumor targeted radionuclide therapy

Targeted Radionuclide Tumor Therapy: Biological Aspects

Volumn , Issue , 2008, Pages 89-116

  Frejd, Fredrik Y ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b Affibody AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649874371     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4020-8696-0_6     Document Type: Chapter

References (110)

1. Behr TM, Gotthardt M, Barth A, Behe M (2001) Imaging tumors with peptide-based radioligands. Q J Nucl Med 45:189-200
2. Britz-Cunningham SH, Adelstein SJ (2003) Molecular targeting with radionuclides: state of the science. J Nucl Med 44:1945-61
3. Russeva MG, Adams GP (2004) Radioimmunotherapy with engineered antibodies Expert Opin Biol Ther 4:217-31
4. Batra SK, Jain M, Wittel UA (2002) Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 13:603-8. Review
5. Heppeler A, Froidevaux S, Eberle AN, Maecke HR (2000) Receptor targeting for tumour localisation and therapy with radiopeptides. Curr Med Chem 7:971-94
6. Tolmachev V, Orlova A, Pehrson R, et al. (2007) Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res 67:2773-82
7. Milenic DE, Brady ED, Brechbiel MW (2004) Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 6:488-99. Review
8. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256:495-7
9. Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 9:1126-36. Review
10. Robinson MK, Doss M, Shaller C (2005) Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 65:1471-8
11. Adams GP, Tai MS, McCartney JE (2006) Avidity-mediated enhancement of in vivo tumor targeting by single-chain Fv dimers. Clin Cancer Res 12:1599-605
12. Olafsen, T et al. (2004) Characterization of engineered anti-p185HER-2 (scFv-CH3) 2 antibody fragments (minibodies) for tumor targeting. Protein Eng Des Sel 17:315-23
13. Tijink BM, Neri D, Leemans CR, et al. (2006) Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med 47:1127-35
14. Olafsen T, Kenanova VE, Wu AM (2006) Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protoc 1:2048-60
15. De Jong M, Valkema R, Jamar F (2002) Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med Apr; 32(2):133-40. Review
16. Reubi JC, Mäcke HR, Krenning EP (2005) Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46(Suppl 1):67S-75S. Review
17. Sharkey RM, Cardillo TM, Rossi EA, et al. (2005) Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 11:1250-5
18. Hey T, Fiedler E, Rudolph R, Fiedler M (2005) Artificial, non-antibody binding proteins for pharmaceutical and industrial applications. Trends Biotechnol 23:514-22
19. Hosse RJ, Rothe A, Power BE (2006) A new generation of protein display scaffolds for molecular recognition. Protein Sci 15:14-27. Review
20. Binz HK, Amstutz P, Pluckthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257-68. Review
21. Binz HK, Pluckthun A (2005) Engineered proteins as specific binding reagents. Curr Opin Biotechnol 16:459-69. Review
22. Nygren PA, Skerra A (2004) Binding proteins from alternative scaffolds. J Immunol Methods 290:3-28. Review
23. Nygren PA, Uhlen M (1997) Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 7:463-9. Review
24. Hoogenboom HR (2005) Selecting and screening recombinant antibody libraries. Nat Biotechnol 23:1105-16. Review
25. Hoogenboom HR (2002) Overview of antibody phage-display technology and its applications. Methods Mol Biol 178:1-37. Review
26. Lipovsek D, Plückthun A (2004) In-vitro protein evolution by ribosome display and mRNA display. J Immunol Methods 290:51-67
27. Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15:553-7
28. Samuelson P, Gunneriusson E, Nygren PA, Stahl S (2002) Display of proteins on bacteria. J Biotechnol 96(2):129-54. Review
29. Chen G, Hayhurst A, Thomas JG (2001) Isolation of high-affinity ligand-binding proteins by periplasmic expression with cytometric screening (PECS). Nat Biotechnol 19:537-42
30. Bertschinger J, Neri D (2004) Covalent DNA display as a novel tool for directed evolution of proteins in vitro. Protein Eng Des Sel 17:699-707
31. Sepp A, Tawfik DS, Griffiths AD (2002) Microbead display by in vitro compartmentalisation: selection for binding using flow cytometry FEBS Lett 532:455-8
32. Hamers-Casterman C, Atarhouch T, Muyldermans S (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446-8
33. Greenberg AS, Avila D, Hughes M et al. (1995) A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374(6518):168-73
34. Nuttall SD, Krishnan UV, Hattarki M, De Gori R, Irving RA, Hudson PJ (2001) Isolation of the new antigen receptor from wobbegong sharks, and use as a scaffold for the display of protein loop libraries. Mol Immunol 38:313-26
35. Coppieters K, Dreier T, Silence K, et al. (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54:1856-66
36. Holt LJ, Herring C, Jespers LS, et al. (2003) Domain antibodies: proteins for therapy. Trends Biotechnol 11:484-90. Review
37. Revets H, De Baetselier P, Muyldermans S (2005) Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 5:111-24. Review
38. Cortez-Retamozo V, Backmann N, Senter PD, et al. (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853-7
39. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, et al. (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98:456-62
40. 99m) Tc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol Feb. 23;1:31-41
41. Li R, Hoess RH, Bennett JS, De Grado WF (2003) Use of phage display to probe the evolution of binding specificity and affinity in integrins. Protein Eng 16:65-72
42. Xu L, Aha P, Gu K (2002) Directed evolution of high-affinity antibody mimics using mRNA display. Chem Biol 9:933-42
43. Parker MH, Chen Y, Danehy F (2005) Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel 18:435-44
44. Koide A, Koide S (2007) Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. Methods Mol Biol 352:95-109
45. Karatan E, Merguerian M, Han Z, et al. (2004) Molecular recognition properties of FN3 monobodies that bind the Src SH3 domain. Chem Biol June; 11:835-44
46. Hufton SE, van Neer N, van den Beuken T (2000) Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands. FEBS Lett 475:225-31
47. Li Y, Moysey R, Molloy PE (2005) Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat Biotechnol 23:349-54
48. Heyd B, Pecorari F, Collinet B (2003) In vitro evolution of the binding specificity of neocarzinostatin, an enediyne-binding chromoprotein. Biochemistry 42:5674-83
49. Lipovsek D, Lippow SM, Hackel BJ (2007) Evolution of an interloop disulfide bond in highaffinity antibody mimics based on fibronectin type III domain and selected by yeast surface display: molecular convergence with single-domain camelid and shark antibodies. J Mol Biol 368:1024-41
50. Beste G, Schmidt FS, Stibora T, Skerra A (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci USA 96:1898-903
51. Schlehuber S, Skerra A (2005a) Anticalins as an alternative to antibody technology. Expert Opin Biol Ther 5:1453-62. Review
52. Schlehuber S, Skerra A (2005b) Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". Drug Discov Today 10:23-33. Review
53. Juraja SM, Mulhern TD, Hudson PJ, et al. (2006) Engineering of the Escherichia coli Im7 immunity protein as a loop display scaffold. Protein Eng Des Sel 19:231-44.
54. Bernath K, Magdassi S, Tawfik DS (2005) Directed evolution of protein inhibitors of DNA-nucleases by in vitro compartmentalization (IVC) and nano-droplet delivery. J Mol Biol 345:1015-26
55. Nilsson B, Moks T, Jansson B, et al. (1987) A synthetic IgG-binding domain based on staphylococcal protein A. Protein Eng 1(2):107-13
56. Nord K, Gunneriusson E, Ringdahl J (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15:772-7
57. Nilsson F Y, Tolmachev V (2007) Affibody molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr Opin Drug Discov Devel 10:167-75. Review
58. Orlova A, Magnusson M, Eriksson TL, et al. (2006) Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res 66:4339-48
59. Tolmachev V, Orlova A, Nilsson F Y, et al. (2007) Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin Biol Ther 7:555-68
60. Tolmachev V, Nilsson FY, Widstrom C, et al. (2006) 111In-benzyl-DTPA- ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med May; 47(5):846-53
61. 99m) Tc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 34:1843-53
62. 99m) Tc-chelating mercaptoacetyl-glycyl-glycylglycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34:722-33
63. Orlova A, Tolmachev V, Pehrson R, et al. (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178-86
64. Feldwisch J, Orlova A, Tolmachev V, Baum RP (2006) Clinical and pre-clinical application of HER2-specific Affibody molecules for diagnosis of recurrent HER2 positive breast cancer by SPECT or PET/CT. Mol Imaging 5(ID045):215
65. Makrides SC, Nygren PA, Andrews B, et al. (1996) Extended in vivo half-life of human soluble complement receptor type 1 fused to a serum albumin-binding receptor. J Pharmacol Exp Ther 277:534-42
66. Silverman J, Liu Q, Bakker A (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23(12):1556-61
67. Forrer P, Stumpp MT, Binz HK, Pluckthun A (2003) A novel strategy to design binding molecules harnessing the modular nature of repeat proteins. FEBS Lett 539:2-6
68. Stumpp MT, Amstutz P (2007) DARPins: a true alternative to antibodies. Curr Opin Drug Discov Devel 10:153-9. Review
69. Binz HK, Amstutz P, Kohl A, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22:575-82
70. Schweizer A, Roschitzki-Voser H, Amstutz P, et al. (2007) Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism. Structure 15:625-36
71. Sennhauser G, Amstutz P, Briand C, et al. (2006) Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors. PLoS Biol 5:106-13
72. Zahnd C, Wyler E, Schwenk JM (2007) A designed ankyrin repeat protein evolved to picomolar affinity to her2. J Mol Biol 369:1015-28
73. Stumpp, MT (2006) Oral presentation at IBC's 2nd Annual International conference on Protein Engineering, December 12-14
74. Otlewski J, Krowarsch D (1996) Squash inhibitor family of serine proteinases. Acta Biochim Pol 43:431-44
75. Gelly JC, Gracy J, Kaas Q, et al. (2004) The KNOTTIN website and database: a new information system dedicated to the knottin scaffold. Nucleic Acids Res 32:D156-9
76. Baggio R, Burgstaller P, Hale SP, et al. (2002) Identification of epitope-like consensus motifs using mRNA display. J Mol Recognit 15(3):126-34
77. Souriau C, Chiche L, Irving R, Hudson P (2005) New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. Biochemistry 44:7143-55
78. Smith GP, Patel SU, Windass JD (1998) Small binding proteins selected from a combinatorial repertoire of knottins displayed on phage. J Mol Biol Mar. 27;277(2):317-32
79. Lehtiö J, Teeri TT, Nygren PA (2000) Alpha-amylase inhibitors selected from a combinatorial library of a cellulose binding domain scaffold. Proteins 41:316-22.
80. Li C, Dowd CS, Zhang W, Chaiken IM (2001) Phage randomization in a charybdotoxin scaffold leads to CD4-mimetic recognition motifs that bind HIV-1 envelope through non-aromatic sequences. J Pept Res 57:507-18.
81. Dennis MS, Lazarus RA (1994) Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. J Biol Chem 269:22129-36
82. Rottgen P, Collins J (1995) A human pancreatic secretory trypsin inhibitor presenting a hypervariable highly constrained epitope via monovalent phagemid display. Gene 164:243-50
83. Williams A, Baird LG (2003) DX-88 and HAE: a developmental perspective. Transfus Apher Sci 29:255-8
84. Legendre D, Vucic B, Hougardy V, et al. (2002) TEM-1 beta-lactamase as a scaffold for protein recognition and assay. Protein Sci 11:1506-18
85. Malabarba MG, Milia E, Faretta M (2001) A repertoire library that allows the selection of synthetic SH2s with altered binding specificities. Oncogene 20(37):5186-94
86. Panni S, Dente L, Cesareni G (2002) In vitro evolution of recognition specificity mediated by SH3 domains reveals target recognition rules. J Biol Chem 277:21666-74
87. Hiipakka M, Saksela K (2007) Versatile retargeting of SH3 domain binding by modification of non-conserved loop residues. FEBS Lett 581:1735-41
88. Schneider S, Buchert M, Georgiev O, et al. (1999) Mutagenesis and selection of PDZ domains that bind new protein targets. Nat Biotechnol 17:170-5
89. Grabulovski D, Kaspar M, Neri D (2007) A novel, non-immunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 282:3196-204
90. Castellani P, Viale G, Dorcaratto A, et al. (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59:612-8
91. Bertschinger J, Grabulovski D, Neri D (2007) Selection of single domain binding proteins by covalent DNA display. Protein Eng Des Sel 20:57-68
92. Brody EN, Gold L (2000) Aptamers as therapeutic and diagnostic agents. Rev Mol Biotechnol 74:5-13. Review
93. Hoppe-Seyler F, Crnkovic-Mertens I, Tomai E, Butz K (2004) Peptide aptamers: specific inhibitors of protein function. Curr Mol Med 4:529-38. Review
94. Ng EW, Shima DT, Calias P, et al. (2006) Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 5:123-32. Review
95. Ireson CR, Kelland LR (2006) Discovery and development of anticancer aptamers. Mol Cancer Ther 5:2957-62. Review
96. Pietras K, Rubin K, Sjöblom T (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-84
97. Pestourie C, Tavitian B, Duconge F (2005) Aptamers against extracellular targets for in vivo applications. Biochimie 87:921-30. Review
98. Charlton J, Sennello J, Smith (1997) In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase D. Chem Biol 4:809-16
99. 99m labeled to antisense DNA. Eur J Nucl Med 27:1700-7
100. Tavitian B, Terrazzino S, Kuhnast B, et al. (1998) In vivo imaging of oligonucleotides with positron emission tomography. Nat Med 4:467-71
101. Hicke BJ, Marion C, Chang YF, et al. (2001) Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276:48644-54
102. Hicke BJ, Stephens AW, Gould T (2006) Tumor targeting by an aptamer. J Nucl Med 47:668-78
103. Matthews SJ, McCoy C (2004) Peginterferon alfa-2a: a review of approved and investigational uses. Clin Ther 26:991-1025. Review
104. Veronese FM, Pasut G (2005) PEGylation, successful approach to drug delivery. Drug Discov Today 10:1451-8. Review
105. Nguyen A, Reyes AE 2nd, Zhang M (2006) The pharmacokinetics of an albumin-binding Fab (AB. Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel 19:291-7
106. Dennis MS, Jin H, Dugger D, et al. (2007) Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. Cancer Res 67:254-61
107. Nygren PA, Uhlén M, Flodby P, et al. (1991) In vivo stabilization of a human recombinant CD4 derivative by fusion to a serum-albumin-binding receptor. Vaccines 91:363-8
108. Vogt M, Skerra A (2004) Construction of an artificial receptor protein ("anticalin") based on the human apolipoprotein D. Chembiochem Feb. 6;5(2):191-9.
109. Nordberg E, Friedman M, Nilsson F, et al. (2006) Biological characterization in vitro and in vivo of a new EGFR binding Affibody molecule. Eur J Nucl Med Mol Imaging 33(Suppl 14):S284.
110. Friedman M, Orlova A, Johansson E, et al. (2008) Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule. J Mol Biol Mar. 7;376:1388-402